PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA

In the given article, the authors discuss the most difficult issue of the pediatrics, which is the treatment of the severe bronchial asthma. Our columnist is professor A.S. Kolbin introduces omalizumab, a new medication from the monoclonal antibodies group, to our readers. It allows practitioners to...

Full description

Saved in:
Bibliographic Details
Main Authors: A.S. Kolbin, N.N. Klimko, B.V. Andreev
Format: Article
Language:Russian
Published: Union of pediatricians of Russia 2008-07-01
Series:Педиатрическая фармакология
Online Access:https://www.pedpharma.ru/jour/article/view/832
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1849394057332129792
author A.S. Kolbin
N.N. Klimko
B.V. Andreev
author_facet A.S. Kolbin
N.N. Klimko
B.V. Andreev
author_sort A.S. Kolbin
collection DOAJ
description In the given article, the authors discuss the most difficult issue of the pediatrics, which is the treatment of the severe bronchial asthma. Our columnist is professor A.S. Kolbin introduces omalizumab, a new medication from the monoclonal antibodies group, to our readers. It allows practitioners to control the severe persistent bronchial asthma. The article accentuates the clinical effectiveness and pharmacoeconomic aspects of the medication application.Key words: bronchial asthma, severe run, treatment, monoclonal antibodies, children.
format Article
id doaj-art-76d8a9bc23fa49c2a3d10bbd709d1995
institution Kabale University
issn 1727-5776
2500-3089
language Russian
publishDate 2008-07-01
publisher Union of pediatricians of Russia
record_format Article
series Педиатрическая фармакология
spelling doaj-art-76d8a9bc23fa49c2a3d10bbd709d19952025-08-20T03:40:11ZrusUnion of pediatricians of RussiaПедиатрическая фармакология1727-57762500-30892008-07-01543844827PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMAA.S. Kolbin0N.N. Klimko1B.V. Andreev2Saint Petersburg State UniversitySaint Petersburg Medical Academy of Postgraduate StudiesSaint Petersburg State UniversityIn the given article, the authors discuss the most difficult issue of the pediatrics, which is the treatment of the severe bronchial asthma. Our columnist is professor A.S. Kolbin introduces omalizumab, a new medication from the monoclonal antibodies group, to our readers. It allows practitioners to control the severe persistent bronchial asthma. The article accentuates the clinical effectiveness and pharmacoeconomic aspects of the medication application.Key words: bronchial asthma, severe run, treatment, monoclonal antibodies, children.https://www.pedpharma.ru/jour/article/view/832
spellingShingle A.S. Kolbin
N.N. Klimko
B.V. Andreev
PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
Педиатрическая фармакология
title PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_full PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_fullStr PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_full_unstemmed PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_short PHARMACOECONOMIC ASPECT OF OMALIZUMAB APPLICATION AMONG THE PATIENTS, SUFFERING FROM THE BRONCHIAL ASTHMA
title_sort pharmacoeconomic aspect of omalizumab application among the patients suffering from the bronchial asthma
url https://www.pedpharma.ru/jour/article/view/832
work_keys_str_mv AT askolbin pharmacoeconomicaspectofomalizumabapplicationamongthepatientssufferingfromthebronchialasthma
AT nnklimko pharmacoeconomicaspectofomalizumabapplicationamongthepatientssufferingfromthebronchialasthma
AT bvandreev pharmacoeconomicaspectofomalizumabapplicationamongthepatientssufferingfromthebronchialasthma